Pfizer said Friday it’s suing Novo Nordisk and obesity biotech Metsera, a day after Novo set off a bidding war against Pfizer to acquire Metsera. A month ago, Pfizer said […]
Read MoreFDA declares Novo Nordisk drug manufacturing plant out of compliance
A troubled Indiana contract manufacturing plant recently acquired by Novo Nordisk is considered to not be in compliance with the Food and Drug Administration standards, a serious designation that could […]
Read Morehealth care CEO net worth, Stealth, Novo
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we examine the plush pay packages of […]
Read MoreNovo Nordisk’s obesity drug Wegovy cleared to treat live disease MASH
Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators on Friday to treat an increasingly common liver disease, adding to the list of conditions for which the blockbuster therapy […]
Read MoreNovo Nordisk’s next-gen obesity drug results a letdown for investors
CHICAGO — Late-stage results of Novo Nordisk’s obesity candidate CagriSema suggest the drug is comparable to Eli Lilly’s Zepbound on safety and efficacy, further data indicating that CagriSema may not […]
Read MoreDosing questions surround Novo Nordisk next-gen weight loss drug
CHICAGO — Novo Nordisk’s next-generation obesity injection targeting the amylin hormone showed substantial weight loss in an early study, but similar efficacy across different doses and high rates of side […]
Read MoreReadout LOUD podcast: FDA AI experiment, Novo trails in obesity
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech […]
Read More